In November 2001, the Food and Drug Administration approved Drotrecogin alfa-activated (DrotAA) for the clinical treatment of adults suffering from severe sepsis and with a high risk of death.
En novembro de 2001, a FDA norteamericana aprobou o uso da Drotrecogin alfa-activada (DrotAA) pra o tratamento clínico de adultos que padecían sepses graves e tiñan un risco alto de morrer.